VTRO — Vitro Biopharma Income Statement
0.000.00%
HealthcareMicro Cap
Annual income statement for Vitro Biopharma, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2014 October 31st | 2015 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.095 | 0.085 | 0.649 | 1.31 | 3.29 |
Cost of Revenue | |||||
Gross Profit | 0.072 | 0.063 | 0.432 | 0.96 | 2.71 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.266 | 0.243 | 1.92 | 5.43 | 9.26 |
Operating Profit | -0.171 | -0.158 | -1.27 | -4.12 | -5.97 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.247 | -0.246 | -1.56 | -4.52 | -6.86 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.247 | -0.246 | -1.56 | -4.52 | -6.86 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.247 | -0.246 | -1.56 | -4.52 | -6.86 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.247 | -0.246 | -1.64 | -4.76 | -7.76 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.012 | -0.012 | -0.014 | -0.041 | -0.059 |